Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Intarcia licenses Servier ex-US/Japan rights to Phase III diabetes therapy

Executive Summary

In one of the largest ex-US biotech partnerships (possibly worth just over $1bn), Intarcia Therapeutics Inc. (drug delivery) granted Servier SA exclusive rights to develop and commercialize its Phase III Type II diabetes candidate ITCA650 (exenatide) worldwide excluding the US (where Intarcia keeps rights) and Japan (where the firm plans to find another partner).
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
  • Medical Devices
    • Implantable Devices
  • Biotechnology
    • Large Molecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)

Related Companies